Breakwater data show significant survival gains over standard chemotherapy

At‑home autoinjector option offers new flexibility for patients and care partners

Non-hormonal option to be made available for patients unsuitable for HRT

Roche therapy accepted for adults ineligible for stem cell transplant

Early-stage study marks milestone for regenerative medicine

New option for adults with IPF and PPF

SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

New phase 3 trial to assess impact on disease progression, function and quality of life

Option offers once‑daily semaglutide tablets for adults living with obesity